Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Artificial intelligence in breast cancer radiotherapy: Insights from the Toolbox Consortium Delphi study
0
Zitationen
12
Autoren
2025
Jahr
Abstract
Artificial intelligence (AI) is being incorporated in several breast cancer care domains, including for radiation therapy (RT). Herein we provide a review about AI for the management and planning of RT for breast cancer, which is part of the Toolbox-3 project's multidisciplinary Delphi study, including a literature review of studies related to the topic raised by the Delphi questionnaire. Our review shows that available evidence mainly consists of small single institutional studies, often at least partly supported by commercial companies. Current studies suffer from a lack of transparency regarding how these systems were developed, the information they are based on, the algorithms used, and potential proprietary issues. This review provides a critical inter- and multidisciplinary assessment of existing systems to help us in guiding development and utilisation of AI-based tools in the field of radiation oncology. As medical professional users, we must remain vigilant and continue to improve our personal experience and knowledge that serves as the "ground truth". Employing AI required a critical mindset, particularly in medical applications which may influence the lives of our patients.
Ähnliche Arbeiten
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
2021 · 85.193 Zit.
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
2009 · 82.801 Zit.
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
2018 · 37.131 Zit.
RoB 2: a revised tool for assessing risk of bias in randomised trials
2019 · 28.346 Zit.
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
2015 · 25.927 Zit.
Autoren
Institutionen
- University of Manchester(GB)
- Maastro Clinic(NL)
- Maastricht University Medical Centre(NL)
- Azienda Ospedaliero-Universitaria Careggi(IT)
- University of Florence(IT)
- Universität Hamburg(DE)
- University Medical Center Hamburg-Eppendorf(DE)
- Champalimaud Foundation(PT)
- University of Antwerp(BE)
- Iridium Kankernetwerk(BE)